Martin Shkreli's Former Company, KaloBios Pharmaceuticals, Files for Bankruptcy

12_30_Shkreli_01
Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs U.S. federal court after an arraignment following his being charged in a federal indictment filed in Brooklyn relating to his management of hedge fund MSMB Capital Management and biopharmaceutical company Retrophin Inc. in New York on December 17. Lucas Jackson/Reuters

(Reuters) - KaloBios Pharmaceuticals Inc , which fired chief executive Martin Shkreli earlier this month, filed for Chapter 11 bankruptcy on Tuesday.

The drugmaker listed both its assets and liabilities in the range of $1 million to $10 million in its filing with the U.S. bankruptcy court for the District of Delaware.

The move comes on the heels of KaloBios' appeal of the Nasdaq decision to delist its shares.

A hearing on the appeal has been scheduled for Feb. 25, KaloBios said on Tuesday.

The company on Monday said two of its directors, Tom Fernandez and Marek Biestekhad, had resigned in the wake of Shkreli's arrest for alleged securities fraud.

KaloBios named Shkreli as its CEO on Nov. 20, after Shkreli and a consortium of investors bought about 70 percent of its shares.

Martin Shkreli gained notoriety when, as the chief executive of Turing Pharmaceuticals, he raised the price of a drug used to treat a dangerous parasitic infection to $750 from $13.50. He resigned as Turing CEO on Dec 18.

Shkreli was arrested on Dec 17 for engaging in what U.S. prosecutors said was a Ponzi-like scheme at his former hedge fund and a pharmaceutical company he previously headed.

KaloBios could not be reached immediately for comment outside regular business hours.

Shares of San Francisco, California-based KaloBios have not traded since last Thursday.

Martin Shkreli's Former Company, KaloBios Pharmaceuticals, Files for Bankruptcy | U.S.